CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

By C. Turtle, L. Hanafi, C. Berger, T. Gooley, S. Cherian, M. Hudecek, D. Sommermeyer, Katherine Melville, B. Pender, Tanya M Budiarto and 13 more. Journal of Clinical Investigation, 2016

1,895 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/46eaade5fa383de46315aa9fb08604363f335881

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management (2018, background): “Intubation and mechanical ventilation may be required for airway protection in obtunded patients [9,11,21].”
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. (2019, background): “org Volume 129 Number 6 June 2019 Neurotoxicity has been reported in up to 50% of subjects in some CAR T cell trials (13, 30, 31), can occur concurrently with or subsequent to CRS, often does not improve with tocilizumab, and is reversible in most, but not all, cases.”
The Principles of Engineering Immune Cells to Treat Cancer (2017, background): “Within the past few years, clinical trials using T cells engineered to recognize B cell cancers have shown high rates of response (70%–90%) and durability of response that are unprecedented in acute (Brentjens et al., 2013; Maude et al., 2014; Turtle et al., 2016) and chronic leukemia (Kalos et al.”
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. (2017, neutral): “13 Median [IQR] 3 [2, 5] 4 [3, 5] 5 [3, 7] 4 [3, 5] Range 1, 11 1, 11 2, 9 1, 11 Prior Transplant, n (%) .”
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma (2017, neutral): “Encephalopathy 34 (34) 13 (13) 21 (21) Confusional state 29 (29) 20 (20) 9 (9) Tremor 29 (29) 28 (28) 1 (1) Aphasia 18 (18) 11 (11) 7 (7) Somnolence 15 (15) 8 (8) 7 (7) Agitation 9 (9) 5 (5) 4 (4) Memory impairment 7 (7) 6 (6) 1 (1) Mental-status change 6 (6) 4 (4) 2 (2)”
Immunotherapy of non-Hodgkin lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells (2016, background): “We observed that treatment with the same lymphodepletion and CD19 CAR-T cell immunotherapy regimen resulted in lower CR rates in NHL and chronic lymphocytic leukemia (CLL) patients compared to B-ALL patients (1, 25).”
Long-term outcomes following CAR T cell therapy: what we know so far (2023, background): “(2023)(51) Mouse scFv, CD8α H/T, 4-1BB co-stimulatory domains; tisagenlecleucel; multicentre phase II Children and young adults aged 3–24 years (79) 39 months 65/79 (82%) Median EFS: 24 months 11/66 (17%) NR”